The market is gradually moving toward personalized treatment strategies based on kidney function, albuminuria, cardiovascular risk, diabetes status, and comorbidities. Treatment selection increasingly considers both efficacy and safety across different stages of CKD. This approach is encouraging development of more targeted therapeutic and monitoring solutions.

The Diabetic Nephropathy Market is entering a new phase of growth as treatment strategies increasingly move beyond glucose control toward comprehensive kidney and cardiovascular protection. Rising diabetes prevalence, earlier chronic kidney disease (CKD) detection, advances in cardiorenal therapies, and growing investment in innovative drug candidates are reshaping the global market.

The Diabetic Nephropathy Market was valued at US$ 4.08 billion in 2025 and is projected to reach US$ 6.96 billion by 2034, expanding at a CAGR of 6.14% during 2026–2034. The market is expected to benefit from increasing adoption of kidney-protective therapies and continued innovation across diabetes and nephrology.

Diabetic Nephropathy Market Overview

Diabetic nephropathy, commonly referred to as diabetic kidney disease (DKD), is a major complication of diabetes that can progressively impair kidney function. Persistent metabolic and vascular abnormalities can contribute to albuminuria, declining estimated glomerular filtration rate (eGFR), CKD, and kidney failure.

The treatment landscape is rapidly evolving. According to the 2026 ADA Standards of Care, SGLT2 inhibitors with demonstrated kidney benefits are recommended for people with type 2 diabetes and CKD, while GLP-1 receptor agonists with demonstrated benefit are also recommended to reduce kidney and cardiovascular risk.

The market is therefore shifting toward a cardiorenal protection model, in which treatment selection considers kidney progression, cardiovascular risk, weight, glucose control, and other comorbidities rather than glycemic control alone.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00008011

Competitive Landscape

The Diabetic Nephropathy Market is characterized by competition among major pharmaceutical and healthcare companies with portfolios spanning diabetes, cardiovascular disease, nephrology, and metabolic disorders.

Key companies include:

• AstraZeneca PLC
• Bayer AG
• Novartis AG
• Novo Nordisk A/S
• Merck & Co., Inc.
• Abbott Laboratories
• Boehringer Ingelheim International GmbH
• AbbVie Inc.
• Pfizer Inc.
• Eli Lilly and Company

Competitive strategies are increasingly centered on expanding indications, strengthening clinical evidence, developing combination approaches, and pursuing therapies that demonstrate measurable renal and cardiovascular outcomes.

The evolving treatment environment is particularly important for companies involved in SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists, diabetes diagnostics, and next-generation kidney therapies.

SGLT2 Inhibitors Strengthen Their Position

SGLT2 inhibitors remain one of the most important therapeutic trends in the diabetic nephropathy market. Their role has expanded from glucose-lowering therapy to kidney and cardiovascular protection.

The 2026 ADA Standards recommend SGLT2 inhibitors for people with type 2 diabetes and CKD at appropriate eGFR levels because of their ability to reduce CKD progression and cardiovascular events. The guideline notes that these benefits occur through mechanisms extending beyond glucose lowering.

This expanding clinical role is expected to support continued demand for SGLT2 inhibitors and create opportunities for companies developing complementary therapies.

GLP-1 Therapies Become Increasingly Important

Another major market trend is the growing role of GLP-1 receptor agonists in diabetic kidney disease. Evidence increasingly supports their relevance beyond glycemic control and weight management.

Recent data from the FLOW program showed that semaglutide reduced the risk of major kidney outcomes in people with type 2 diabetes and CKD, reinforcing interest in GLP-1-based approaches within the renal treatment landscape.

Oral GLP-1 therapy is an especially emerging area. Results from the 2026 SOLID-DKD phase 2 trial showed that the oral small-molecule GLP-1 receptor agonist HRS-7535 reduced albuminuria in patients with diabetic kidney disease receiving contemporary background treatment. The findings support further evaluation in phase 3 renal-outcome trials.

Combination Therapy and the Four-Pillar Approach

Combination therapy is becoming one of the most important developments in diabetic nephropathy treatment. Rather than relying on a single mechanism, researchers and clinicians are increasingly examining complementary approaches targeting different pathways involved in CKD progression.

The 2026 ADA Standards state that simultaneous initiation of an SGLT2 inhibitor and the nonsteroidal mineralocorticoid receptor antagonist finerenone can be considered in selected adults with type 2 diabetes, CKD, albuminuria, and appropriate eGFR.

Recent reviews have also highlighted a potential four-pillar approach involving RAAS blockade, SGLT2 inhibitors, nonsteroidal MRAs, and GLP-1 receptor agonists. This reflects the broader shift toward multidimensional cardiorenal risk reduction.

KDIGO 2026 Guideline Update

The KDIGO 2026 Diabetes and CKD Guideline Update is another important current development for the market. KDIGO released a draft for public review in March 2026, incorporating clinical and scientific developments since its 2022 guideline. The update focuses on definitions, prevention and risk assessment, glycemic monitoring, and comprehensive pharmacotherapy.

For market participants, evolving guidelines are significant because treatment recommendations can influence physician adoption, patient management pathways, pharmaceutical demand, and the competitive positioning of therapies.

Emerging Pipeline and Precision Medicine

The next stage of diabetic nephropathy innovation is likely to extend beyond established drug classes. Current research is exploring additional mechanisms, including endothelin receptor antagonists, aldosterone synthesis inhibitors, and Janus kinase inhibitors.

At the same time, biomarker-based risk assessment and precision medicine are becoming increasingly relevant. Better identification of patients at high risk of kidney-function decline could enable earlier intervention and more individualized treatment strategies.

Future Outlook

The Diabetic Nephropathy Market is expected to remain on a strong growth trajectory through 2034. The market’s development will increasingly be influenced by therapies that demonstrate kidney and cardiovascular benefits rather than focusing exclusively on glucose reduction.

SGLT2 inhibitors, GLP-1 receptor agonists, finerenone-based treatment, combination therapy, oral GLP-1 drugs, biomarkers, and precision medicine are among the trends expected to shape the competitive environment.

Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish

Related Reports:

Dental Pain Management Market Trends, Size & Forecast by 2034

Stomach Cancer Therapeutics Market Trends, Demand & Growth by 2034

About Us

The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.

Contact Us

Contact Person: Ankit Mathur

Phone: +1-646-491-9876

E-mail : sales@theinsightpartners.com